Physician profile
Ania E Janicka
NPI 1538353305
$474,939.67
in general payments reported to CMS, 2019-2025
57 companies · $163K in 2025
The $163K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $48K · 2021: $44K · 2022: $82K · 2023: $40K · 2024: $53K · 2025: $163K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $135K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $67K · Travel and Lodging: $29K · Food and Beverage: $15K · Consulting Fee: $5,989 · Honoraria: $3,400 · Education: $37.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $135,301.94 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $67,298.76 |
| Travel and Lodging | $28,723.84 |
| Food and Beverage | $15,386.88 |
| Consulting Fee | $5,989.00 |
| Honoraria | $3,400.00 |
| Education | $37.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $218,048.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $138,418.64 | 2019-2025 | Omnipod, Omnipod |
| Dexcom, INC. | $52,700.54 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbott Laboratories | $20,186.69 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $15,093.74 | 2019-2023 | Steglatro, Steglujan |
| Amryt Pharma Holdings Ltd | $9,259.05 | 2021-2023 | Mycapssa |
| Chiesi USA, INC. | $4,925.81 | 2024-2025 | Mycapssa |
| Valeritas, INC. | $3,200.28 | 2019 | |
| Zealand Pharma US, INC. | $2,014.63 | 2020-2022 | |
| Lilly USA, LLC | $1,209.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,019.33 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $961.18 | 2019-2025 | |
| Corcept Therapeutics | $807.98 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $645.94 | 2022-2025 | |
| Tandem Diabetes Care, INC. | $583.13 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ania Janicka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.